Navigation Links
National Health Education Campaign: "When Will You Pick?"™ Encourages Families to Make Flu Vaccination a Priority This Fall
Date:9/21/2010

lty with breathing) after getting FluMist.

Who may not be able to get FluMist?

Tell your healthcare provider if you: are currently wheezing; have a history of wheezing if under 5 years old; have had Guillain-Barre syndrome; have a weakened immune system or live with someone who has a severely weakened immune system; have problems with your heart, kidneys, or lungs; have diabetes; are pregnant or nursing; or are taking Tamiflu®, Relenza®, amantadine, or rimantadine.

They will decide if FluMist is right for you.

What are the most common side effects of FluMist?

The most common side effects of FluMist are runny or stuffy nose; sore throat and fever over 100 degrees F.

Please see accompanying complete Product Information, including Patient Information.

For more information, please visit www.FluMist.com.

About MedImmune

MedImmune, the worldwide biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at http://www.medimmune.com/.

About Women's Professional Soccer

The world's premier women's professional soccer league, Women's Professional Soccer began play in 2009 and is dedicated to becoming the global standard for women's professional sports. This year, the WPS includes seven teams: Atlanta Beat, Boston Breakers, Chicago Red Stars, FC Gold Pride from the Bay Area, Sky
'/>"/>

SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Waismann Method Supports National Take-Back Initiative
2. ThanksUSA Awards Scholarships to Military Families With the Help of the National Association of Chain Drug Stores
3. National Institutes of Health Chooses ScriptPro for Pharmacy Automation
4. Olympus Launches 2011 National Innovation Awards Program
5. National Survey of Physicians Reveals Common Misperceptions Concerning Misuse and Abuse of Opioids in Light of New Government Statistics
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at UBS Global Life Sciences Conference
7. GBS/CIDP Foundation to Hold 11th International Symposium
8. Sono-Tek Presents at the 15th International Coating Science and Technology Symposium (ISCST, St. Paul, MN)
9. Reportlinker Adds Pharmaceutical Preparation Manufacturing Industry in the U.S. and Its International Trade [Q3 2010 Edition]
10. Landmark National Survey Conducted by Harris Interactive® Sheds Light on Hidden Problem of Heavy Monthly Periods
11. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... WOODCLIFF LAKE, N.J. and STAMFORD, ... the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and ... into a worldwide collaboration agreement for the development and ... a dual orexin receptor antagonist entering Phase III clinical ... Under the terms of the agreement, Eisai and Purdue ...
(Date:8/31/2015)... Australia , Aug. 31, 2015 Bionomics ... discovery and development of innovative therapeutics for the treatment ... cancer, today announced that its BNC101 IND submission has ... (FDA). Bionomics plans to initiate a Phase 1 clinical ... patients with metastatic pancreatic cancer prior to 31 December ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
(Date:9/1/2015)... ... September 01, 2015 , ... ... borders seldom arise at the most convenient time for everyone involved. These occasions ... help. , Universal Translation Services has real people available to handle ...
(Date:9/1/2015)... ... 2015 , ... Dr. Trace Curry successfully placed one of the first ORBERA™ ... month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed Weight ... incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, medical ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... to send information about new patients directly from Practice Perfect to FOTO enabling ... data entry. , Steven Presement, President of Practice Perfect, stated ...
(Date:9/1/2015)... ... September 01, 2015 , ... Anthony J. Tantillo, Esq., Attorney from ... his third consecutive year in a row. Through nomination, research and strategic evaluation ... Born in Niagara Falls, New York, Tantillo is a Buffalo State College graduate of ...
(Date:9/1/2015)... ... September 01, 2015 , ... MediNatura™, the exclusive ... workshop for physician assistants (PAs) practicing in orthopedics. The workshop, titled “Treatment of ... by Dr. Erick Salado, an orthopedic surgeon at South Florida Bone and Joint ...
Breaking Medicine News(10 mins):Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... May 19, 2009 (OAKLAND, Calif.) An e-mail intervention ... and physical activity by helping people move more, sit ... Kaiser Permanente Division of Research study in the ... was a randomized controlled trial of the ALIVE (A ...
... LIFE Event raises $500,000 for breast cancer bringing total ... Twenty-eight LPGA pros including World Golf Hall of ... players Angela Stanford, Morgan Pressel, Brittany Lincicome, Helen Alfredsson, ... for the 10th anniversary LIFE (LPGA Pros in the ...
... MEETING, Pa., May 18 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... the first quarter ended March 31, 2009. , , ... -- First quarter revenues increased to $39.3 million ... prior year period., -- Gross profit increased to ...
... 18 Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... on May 14, 2009 it received official notification from Nasdaq that ... requirements as set forth in Listing Rule 5605. Under Nasdaq ... regain compliance as follows: , , ...
... Pharmaceuticals, Inc. (Nasdaq: TRBN ) announced today ... 2b study (15002) of TRU-015 for rheumatoid arthritis will ... League Against Rheumatism (EULAR) annual meeting in Copenhagen, Denmark. ... http://www.eular.org/ .(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ...
... The Quigley Corporation, (Nasdaq: QG L ... , today announced an update on the Company,s ... announcement regarding the unexpected positive finding for its QR-333 ... 11b clinical trial. While the complete statistical results of ...
Cached Medicine News:Health News:Workplace e-mail intervention program helps people sit less and eat better 2Health News:Workplace e-mail intervention program helps people sit less and eat better 3Health News:LIFE 10th Anniversary Event Delivers Big Names and Big Dollars for Breast Cancer Fight 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 3Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 4Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 5Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 6Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 7Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 8Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 9Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 10Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 11Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 2Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 2Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 4Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 2Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 3Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 4
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: